Compare PTCT & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | WH |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.4B |
| IPO Year | 2006 | 2017 |
| Metric | PTCT | WH |
|---|---|---|
| Price | $72.07 | $81.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | $80.65 | ★ $94.10 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ 0.80 |
| Revenue | $264,734,000.00 | ★ $1,429,000,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | $17.70 | $5.83 |
| P/E Ratio | ★ N/A | $99.61 |
| Revenue Growth | ★ 36.19 | 1.49 |
| 52 Week Low | $43.18 | $69.21 |
| 52 Week High | $87.50 | $92.69 |
| Indicator | PTCT | WH |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 50.35 |
| Support Level | $68.49 | $79.69 |
| Resistance Level | $73.17 | $82.54 |
| Average True Range (ATR) | 2.40 | 2.57 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 70.34 | 62.41 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.